Background
==========

Lung cancer, an extremely heterogeneous disease, accounts for almost a quarter of cancer-related deaths \[[@b1-medscimonit-23-2453]\]. Lung adenocarcinoma (LUAD) is the most aggressive histological type of lung cancer. The incident of LUAD has been increasing rapidly \[[@b2-medscimonit-23-2453]\]. Unfortunately, LUAD mortality has not significantly decreased owing to the lack of early detection and lack of more effective therapies at earlier disease stages. Therefore, insights into the mechanisms of LUAD are considered urgent.

MicroRNAs (miRNAs or miRs), typically 18--23 nucleotides in length, have gained much attention as oncogenes or suppressors modulating gene activity at the post-transcriptional and translational levels \[[@b3-medscimonit-23-2453]\]. Numerous studies have shown that aberrantly expressed miRNAs in various types of cancer are associated with cell development, cell proliferation, apoptosis, and tumorigenesis \[[@b4-medscimonit-23-2453]--[@b7-medscimonit-23-2453]\].

Growing evidence has demonstrated that downregulated miR-375 expression contributes to various types of cancers. Several studies have reported that downregulated miR-375 expression was implicated in β-cell growth and glucose regulation of insulin gene expression by directly targeting PDK1 in pancreatic carcinoma \[[@b8-medscimonit-23-2453],[@b9-medscimonit-23-2453]\]. In addition, miR-375 has been shown to inhibit cancer cell growth in liver cancer by negatively regulating oncogene AEG-1 \[[@b10-medscimonit-23-2453]\]. MiR-375 is considered as an oncomiR in prostate carcinogenesis and plays a vital role in prostate cancer progression \[[@b11-medscimonit-23-2453]\].

In non-small cell lung carcinoma (NSCLC), decreased miR-375 expression level was significantly correlated with lymphatic metastasis and advanced stage disease. On the contrary, high miR-375 expression could also promote cell migration and target CLDN1 in NSCLC \[[@b12-medscimonit-23-2453]\]. In a previous study, miR-375 expression levels were significantly over-expressed in LUAD and small cell lung carcinoma (SCLC), whereas they were under-expressed in lung squamous cell carcinoma (LUSC) \[[@b13-medscimonit-23-2453]\]. Furthermore, studies have also found that miR-375 promotes cell growth in SCLC cell lines by directly downregulating inositol-trisphosphate 3-kinase B (ITPKB) \[[@b14-medscimonit-23-2453]\]. Unfortunately, data published on miR-375 expression in LUAD are partly conflicting and highly heterogeneous.

In the present study, we sought to unveil the role of miR-375 in LUAD through modulation of miRNAs expression and identification of putative molecular targets by bioinformatics analysis and analysis based on TCGA, GEO, and literature reviews.

Material and Methods
====================

TCGA data in LUAD patients
--------------------------

The available data on miR-375 expression and clinical information were obtained from Illumina HiSeq Level 3 isoform quantification files available at the TCGA Data Portal website (*<http://tcga.cancer.gov/dataportal>*; accessed June 2016). We obtained the normalized reads per million miRNA mapped (RPM) data in 517 LUAD patients and 59 normal lung samples by summing up the raw counts. The RPM data of the miR-375 identified in this study were extracted both for 450 LUAD patients and 47 normal samples. Mean values were used for a patient with more than one portion to prevent duplicates. The LIMMA package of R language was used to identify the differentially expressed genes (DEGs) between the expression profiles of 517 LUAD patients and 59 normal samples. We identified the significance of gene expression difference by using absolute log2 fold change (FC) \>1. FDR (False Discovery Rate) of q-value was adjusted to 0.05.

Selection of GEO dataset
------------------------

Next, we obtained the microarray profiles of LUAD from the GEO database (Gene Expression Omnibus, *<http://www.ncbi.nlm.nih.gov/geo/>*). The following keywords were used in the GEO database: (lung OR pulmonary OR respiratory OR bronchi OR bronchioles OR alveoli OR pneumocytes OR "air way") AND (cancer OR carcinoma OR tumor OR neoplas\* OR malignan\* OR adenocarcinoma) AND (microRNA OR miRNA OR "micro RNA" OR "small temporal RNA" OR "noncoding RNA" OR ncRNA OR "small RNA"). The microarray datasets reporting miR-375 expression between LUAD and normal lung tissues was included in this study.

Study selection and data extraction for literature review
---------------------------------------------------------

An electronic literature search was performed in PubMed and Web of Science (up to September 1, 2016) by using the following terms: (miR-375 OR miRNA-375 OR microRNA375 OR miR375 OR miRNA375 OR miR 375 OR miRNA 375 OR microRNA 375) and (lung cancer OR lung carcinoma OR lung neoplasm OR lung tumor OR lung adenocarcinoma OR LUAD OR non-small cell lung cancer OR NSCLC). Publications were considered eligible if they met the following criteria: (1) studies examining the expression of miR-375 in LUAD; and (2) normal lung tissues paired/unpaired used as healthy control group. The studies were considered ineligible based on the following criteria: (1) reviews, experimental studies, single case reports, meta-analyses, and conference abstracts; and (2) absence of healthy control groups.

Gene ontology enrichment and target prediction analysis
-------------------------------------------------------

The targets of miR-375 were predicted through 12 programs, including miRWALK2.0 (*<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/miRretsys-self.html>*). To increase the prediction accuracy, the genes were selected as targets that were overlapped in at least 5 of 12 databases (Microt4, miRWalk, mirbridge, miRanda, miRDB, miRMap, Pictar2, PITA, miRNAMap, RNAhybrid, RNA22 and Targetscan). Subsequently, we analyzed the gene overlaps integrated between DEGs in LUAD, and predicted target genes of miR-375 by bioinformatics software. Gene ontology (GO) enrichment analysis was conducted for overlapped genes by DAVID \[[@b15-medscimonit-23-2453]\]. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (*<http://www.genome.jp/kegg/tool/search_pathway.html>*) was then used to map the predicted targets by using DAVID online analysis (*<https://david.ncifcrf.gov/>*) \[[@b16-medscimonit-23-2453]\]. STRING database (the Search Tool for the Retrieval of Interacting Genes/Proteins) was also used to predict the association between miR-375 and the target gene in the regulatory network analysis \[[@b17-medscimonit-23-2453]\].

Statistical analysis
--------------------

All data are displayed as mean ± standard deviation (SD) from each group. Student's *t*-test was performed to analyze the differences between two groups, whereas one-way analysis of variance (ANOVA) test was used among more than three groups. Standardized mean difference (SMD) was applied to evaluate the association between miR-375 levels and LUAD by RevMan 5.2.0 software. We pooled the SMD across GEO datasets using the Mantel-Haenszel formula (fixed-effect model) or the DerSimonian-Laird formula (random-effect model). A fixed-effect model was adopted when the Q statistic was considered significant (*p*\>0.1, or I^2^\<50%), otherwise, a random-effect model was used. Moreover, the relationship of DEGs expression with miR-375 level was analyzed by Spearman's rank correlation. A two-sided *p*-value \<0.05 was considered statistically significant.

Results
=======

MiR-375 expression in LUAD clinical tissues
-------------------------------------------

### The detection of MiR-375 expression in LUAD in TCGA

The expression levels of miR-375 were significantly upregulated in clinical LUAD specimens (14.0282±1.86840) in comparison to adjacent non-cancerous lung tissues (12.7962±1.38416; *p*\<0.0001, [Figure 1](#f1-medscimonit-23-2453){ref-type="fig"}). For all the tested parameters, no significant differences were found in the other clinical features ([Table 1](#t1-medscimonit-23-2453){ref-type="table"}).

MiR-375 expression in LUAD based on GEO
---------------------------------------

Additionally, miR-375 expression was initially assessed in a series of LUAD and normal lung tissues based on GEO dataset ([Figure 2](#f2-medscimonit-23-2453){ref-type="fig"}). A total of seven GEO datasets (GSE40738, GSE47525, GSE48414, GSE51853, GSE74190, and GSE25508) which included both LUAD patients and healthy people, were collected in our study. The expression levels of miR-375 in LUAD tissues were significantly higher than in healthy non-cancer control tissues in GSE48414, GSE51853, GSE63805, and GSE74190 datasets (*p*=0.012, *p*=0.009, *p*=0.003, and *p*\<0.0001; respectively), whereas no significant difference was found in other GEO datasets (GSE40738, GSE47525, and GSE25508). Characteristics of studies based on GEO dataset are presented in [Table 2](#t2-medscimonit-23-2453){ref-type="table"} and [Figure 3](#f3-medscimonit-23-2453){ref-type="fig"}. However, no significant difference was found between LUAD and control groups based on all the included GEO datasets (SMD=0.33; 95% CI, −0.16 to 0.82; *p*=0.18) with significant heterogeneity by random-effected model (*p*\<0.0001, I^2^=79%). The results of forest plot and funnel plot are shown in [Figure 4](#f4-medscimonit-23-2453){ref-type="fig"}.

Literature review of miR-375 expression profiles in LUAD versus normal lung
---------------------------------------------------------------------------

Next, we explored miR-375 upregulation in LUAD based on literature data. As shown in [Figure 5](#f5-medscimonit-23-2453){ref-type="fig"}, five studies that met the criteria for selection were selected from the literature \[[@b14-medscimonit-23-2453],[@b18-medscimonit-23-2453]--[@b21-medscimonit-23-2453]\]. Consistent with the result of TCGA, a common pattern of upregulation for miR-375 in LUAD were reported across the four included studies, whereas no significant upregulation was found in one study ([Table 3](#t3-medscimonit-23-2453){ref-type="table"}).

MiR-375 prediction and bioinformatics analyses
----------------------------------------------

### Data preprocessing and DEGs screening

A total of 20,531 genes were differentially compared in LUAD TCGA data. After preprocessing, 5,817 DEGs were screened out by the difference threshold (q value \<0.05 and absolute log~2~FC \>1), including 3,843 upregulated genes and 1,794 downregulated genes. Meanwhile, 58,976 target genes for miR-375 were identified in five up-to-date prediction algorithms. Furthermore, all the 682 miR-375 predicted target genes were sorted out by language R, which were then integrated analytically between DEGs and the predicted target genes. The flow diagram and results for DEGs screening process are depicted in [Figures 6](#f6-medscimonit-23-2453){ref-type="fig"} and [7](#f7-medscimonit-23-2453){ref-type="fig"}.

Functional analysis of the DEGs in lung cancer
----------------------------------------------

First, we identified the functional roles of 682 potential target genes in terms of biological processes in LUAD by GO enrichment analysis. The analysis revealed that numerous target genes were involved in the biological processes, such as neuron differentiation, plasma membrane part and sequence-specific DNA binding. Then, the KEGG pathways program was used to reveal the critical pathway, in which the overrepresentation of the predicted miR-375 targets was involved, linked to carcinogenesis such as pentose and glucuronate interconversions, ascorbate and aldarate metabolism, and starch and sucrose metabolism. The top ten GO processes and KEGG pathways that were most strongly enriched with respect to miR-375 in LUAD are shown in [Tables 4](#t4-medscimonit-23-2453){ref-type="table"}, [5](#t5-medscimonit-23-2453){ref-type="table"}, and [Figure 8](#f8-medscimonit-23-2453){ref-type="fig"}.

Protein-protein interaction network analysis
--------------------------------------------

STRING was performed to construct the PPI network based on the overlapped DEGs and genes or proteins ([Figure 9](#f9-medscimonit-23-2453){ref-type="fig"}). In the PPI network, FGF2 (fibroblast growth factor 2), PAX6 (paired box 6), and RHOJ were revealed to exert their potential roles in LUAD by interactions with miR-375 ([Table 6](#t6-medscimonit-23-2453){ref-type="table"}). The expression of three genes were downregulated in LUAD (log~2~FC=−2.11, FDR \<0.0001; log~2~FC=−1.431, FDR \<0.0001 and log~2~FC=−1.879, FDR \<0.0001, respectively). A significant negative correlation was observed between FGF2 and miR-375 expression in LUAD patients by Spearman correlation (r=−0.1821, *p*=0.0001), whereas no significant correlation was found between PAX6 and RHOJ and miR-375 (*p*=0.1221 and *p*=0.325, respectively; [Figure 10](#f10-medscimonit-23-2453){ref-type="fig"}).

Discussion
==========

In this study, we identified the aberrantly expressed miR-375 involved in LUAD through the comparison of miRNA expression profiles in cancerous tissues with that of normal lung tissues based on validation from TCGA and GEO datasets and published studies. Additionally, we discovered novel markers and potential targets for miR-375 that were involved in the regulation of crucial biological processes in LUAD by GO analysis and KEGG pathway annotation.

To date, there have only been several studies concerning the characteristics of miR-375 in lung cancer. Li et al. were the first to demonstrate that the expression of miR-375 was lower in 96 paired samples of NSCLC tissue than in matched noncancerous tissue \[[@b22-medscimonit-23-2453]\]. On the contrary, Yoda et al. revealed that miR-375 was overexpressed in 54 LUAD patients as compared with normal controls by qRT-PCR \[[@b19-medscimonit-23-2453]\]. Additionally, another current report on miR-375 expression in LUAD was consistent with a previous study that reported miR-375 was overexpressed in microarray profiles selected LCM cancerous cell populations derived from 36 LUADs \[[@b14-medscimonit-23-2453]\]. We also found that miR-375 was constantly upregulated in LUAD tissues in TCGA data and several GEO datasets. To date, the result of the expression of miR-375 level in LUAD is still controversial, and further investigation is required to elucidate the role of miR-375 in LUAD.

Recently, it has been suggested that miR-375 targets several important genes to suppress core hallmarks of cancer, such as YAP1 (yes-associated protein), IGF1R, PDK1, and AEG-1 \[[@b9-medscimonit-23-2453],[@b10-medscimonit-23-2453],[@b23-medscimonit-23-2453],[@b24-medscimonit-23-2453]\]. In gastric cancer, miR-375 could target PDK1 and Janus kinase 2, which consequently could reduce cell viability and suppress gastric cancer cell proliferation \[[@b25-medscimonit-23-2453],[@b26-medscimonit-23-2453]\]. Xu et al. demonstrated that the overexpression of miR-375 remarkably suppressed consequent cell invasion and metastasis by downregulating FZD8 in colorectal cancer \[[@b27-medscimonit-23-2453]\]. It was reported that AEG-1 and YAP were regulated by miR-375, and inhibited proliferation and invasion of cancer cells in hepatocellular carcinoma \[[@b10-medscimonit-23-2453],[@b28-medscimonit-23-2453]\]. MiR-375 has been revealed to act as a tumor suppressor in human cancers, whereas it functions as an oncogene in some types of cancers. It has been shown that miR-375 overexpression facilitated cell proliferation and upregulated estrogen receptor alpha through regulation of RASD1 in breast cancer \[[@b29-medscimonit-23-2453]\]. Nishikawa et al. demonstrated that miR-375 was induced by ASH1/ASCL1 in lung cancer cells, which is a key transcription factor in lung cancer with neuroendocrine features. Additionally, Yoda et al. found that high miR-375 expression promoted cell invasion and metastasis in NSCLC by targeting CLDN1 \[[@b12-medscimonit-23-2453]\]. Yu et al. also found that miR-375 was consistently overexpressed in LUAD, displaying higher accuracy in diagnosis of LUAD compared with LUSC \[[@b18-medscimonit-23-2453]\]. Hamaoto et al. hypothesized that miR-375 could inactivate the PI3K pathway, which is more activated in SCC than in AC \[[@b19-medscimonit-23-2453],[@b30-medscimonit-23-2453]\]. Thus, the molecular mechanism that is related to miR-375 overexpression in LUAD has not yet been fully elucidated.

In the present study, we identified that novel candidate target genes for miR-375 were involved in the regulation of crucial biological processes in LUAD, such as FGF2, PAX6, and RHOJ. FGF2, the most potent FGF increased in NSCLC, promotes proliferation and inhibits apoptosis of lung cancer cells. FGF2 could also promote cell malignant transformation by combining with FGFR in LUAD \[[@b31-medscimonit-23-2453]\]. Interestingly, our current study revealed that FGF2 mRNA was decreased in LUAD compared with normal lung tissue. Consistent with our result, both upregulation and downregulation of FGF2 have also been detected in colorectal cancers \[[@b32-medscimonit-23-2453],[@b33-medscimonit-23-2453]\]. As far as we know, few previous studies have indicated that the downregulated pattern of FGF2 occurs in tumor tissue compared with normal tissue. FGF2 is an important proangiogenic growth factor in the promotion of development and in tumor angiogenesis \[[@b34-medscimonit-23-2453]\]. Thus, further investigation is required to explore the ectopic expression of FGF2 of LUAD cells. The transcription factor PAX6 has an oncogenic role that has different signaling pathways in different tumors. A previous study showed that PAX6 was highly expressed in lung cancer tissues and lung cancer cell lines, suggesting that PAX6 promoted the cell cycle progression in lung cancer by activating the MET tyrosine kinase receptor gene and MAPK signaling \[[@b35-medscimonit-23-2453]\]. On the contrary, our study demonstrated that PAX6 mRNA expression level was stronger in normal lung tissue than in lung cancer tissue. In light of previous studies, PAX6 is also recognized as a tumor suppressor in several cancers \[[@b36-medscimonit-23-2453]--[@b38-medscimonit-23-2453]\]. PAX6 suppresses cell growth, angiogenesis, and invasiveness of glioma by inhibiting vascular endothelial growth factor A and matrix metalloproteinase-2 \[[@b39-medscimonit-23-2453],[@b40-medscimonit-23-2453]\]. In support of the presented evidence, we hypothesize that PAX6 functioned as a tumor suppressor in LUAD. Additionally, RhoJ has been revealed to be down-expressed in LUAD, which has previously been considered as a selective and effective therapeutic target in tumor tissues. Previous studies employing animal tumor models showed that the genetic deletion of host-derived RhoJ could inhibit tumor progression and metastasis by suppressing tumor angiogenesis. Recently published studies also demonstrated that RhoJ is involved in the progression of gastric cancer by positively regulating tumor cell motility and invasiveness. Our study was the first to report the potential role of RhoJ in LUAD. Further studies are needed to validate the therapeutic role of RhoJ in LUAD.

Conclusions
===========

Altogether, the results presented here indicate that miR-375 exerts a vital role in the biology of LUAD. Further studies *in vitro* and *in vivo* are required on the mechanisms of pathogenesis to elucidate the potential role of miR-375-regulated molecular networks and gain insights into the mechanism underlying the involvement of miR-375 in LUAD.
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###### 

Clinical covariates for the TCGA LUAD cohort.

  Clinicopathological feature   n         miRNA-375 relevant expression(2^−ΔCq^)                                                                                 
  ----------------------------- --------- ---------------------------------------- ----------------- ----------------------------------------------------------- ----------
  Tissue                        LUAD      450                                      14.0282±1.86840   5.542                                                       \<0.0001
  Normal lung                   46        12.7962±1.38416                                                                                                        
  Age (years)                   \<60      121                                      13.9739±1.7431    −0.156                                                      0.876
  ≥60                           310       14.0050±1.9093                                                                                                         
  Gender                        Male      210                                      14.1536±2.0444    1.317                                                       0.189
  Female                        240       13.9185±1.6963                                                                                                         
  Tumor stage 1                 T1        154                                      13.8402±2.0764    1.834[\*](#tfn1-medscimonit-23-2453){ref-type="table-fn"}   0.14
  T2                            236       14.1677±1.8113                                                                                                         
  T3                            41        13.6755±1.3020                                                                                                         
  T4                            16        14.5330±1.7740                                                                                                         
  Tumor stage 2                 T1\~2     390                                      14.0384±1.9244    0.46                                                        0.646
  T3\~4                         57        13.9162±1.4849                                                                                                         
  Nodes                         Yes       156                                      14.0911±1.7676    0.501                                                       0.616
  No                            293       13.9981±1.9243                                                                                                         
  Metastasis                    Yes       159                                      13.9730±1.8354    −0.486                                                      0.627
  No                            287       14.0630±1.8934                                                                                                         
  Pathologic stage 1            I         242                                      13.9870±1.9997    0.357[\*](#tfn1-medscimonit-23-2453){ref-type="table-fn"}   0.784
  II                            110       13.9973±1.7651                                                                                                         
  III                           73        14.1602±1.5368                                                                                                         
  IV                            20        14.3416±1.8340                                                                                                         
  Pathologic stage 2            I+II      352                                      13.9903±1.9270    −0.962                                                      0.337
  II+IV                         93        14.1992±1.5964                                                                                                         
  Anatomic organ subdivision    L_lower   70                                       14.0738±1.9777    0.985[\*](#tfn1-medscimonit-23-2453){ref-type="table-fn"}   0.415
  L_upper                       109       14.0742±1.8623                                                                                                         
  R_lower                       85        14.1820±1.8741                                                                                                         
  R_middle                      156       13.8154±1.8411                                                                                                         
  R_upper                       19        14.5101±1.8248                                                                                                         
  Location                      Central   54                                       13.8303±1.9611    −1.03                                                       0.305
  Peripheral                    113       14.1516±1.8495                                                                                                         

One-way analysis of variance (ANOVA) test was performed.

###### 

Characteristics of studies based on GEO dataset.

  Study      Patients                                                     Control   t     P                                 
  ---------- ------------------------------------------------------------ --------- ----- ---------- -------- ---- -------- -------
  GSE25508   2.2384                                                       0.4558    5     2.2886     0.5715   5    −0.154   0.882
  GSE40738   −0.5367                                                      0.1091    45    −0.4921    0.1438   91   −1.836   0.069
  GSE47525   10.3833                                                      5.7049    6     10.4780    5.4595   14   −0.035   0.972
  GSE48414   −0.0060                                                      1.9080    154   −0.48466   0.4753   20   2.560    0.012
  GSE51853   0.8610                                                       1.9923    76    0.1738     0.2469   5    2.708    0.009
  GSE63805   2.3994                                                       0.4889    32    2.1065     0.1761   30   3.176    0.003
  GSE74190   6.0000                                                       1.8560    46    4.3600     0.8690   44   4.871    0.000
  Total      SMD(95%CIs)=0.33(−0.16, 0.82), P=0.18; I^2^=79%, P\<0.0001                                                     

###### 

Overview of the 5 studies selected from literature.

  Author     Year   Country    LUAD (n)   Normal lung (n)   Result          Detection methods
  ---------- ------ ---------- ---------- ----------------- --------------- ----------------------
  Yu         2010   Maryland   36         36 (paired)       Up-regulation   qRT-PCR
  Hamamoto   2013   Japan      54         54 (paired)       Up-regulation   qRT-PCR
  Sonia      2014   Spain      19         19 (paired)       Up-regulation   qRT-PCR
  Jin        2015   China      36         44                Up-regulation   qRT-PCR
  KIM        2014   Korea      35         2                 NS              MicroRNA microarrays

###### 

Ten processes most strongly enriched by GO analysis.

  Category                   Term                                                                 Count   P-value    FDR
  -------------------------- -------------------------------------------------------------------- ------- ---------- ----------
  **Biological processes**                                                                                           
  GOTERM_BP_FAT              GO: 0030182\~neuron differentiation                                  52      1.58E-12   2.79E-09
  GOTERM_BP_FAT              GO: 0048666\~neuron development                                      44      5.76E-12   1.02E-08
  GOTERM_BP_FAT              GO: 0007409\~axonogenesis                                            32      1.39E-11   2.45E-08
  GOTERM_BP_FAT              GO: 0000902\~cell morphogenesis                                      44      2.96E-11   5.23E-08
  GOTERM_BP_FAT              GO: 0048812\~neuron projection morphogenesis                         33      4.00E-11   7.06E-08
  GOTERM_BP_FAT              GO: 0048667\~cell morphogenesis involved in neuron differentiation   32      1.13E-10   1.99E-07
  GOTERM_BP_FAT              GO: 0006928\~cell motion                                             50      3.40E-10   5.99E-07
  GOTERM_BP_FAT              GO: 0000904\~cell morphogenesis involved in differentiation          34      3.40E-10   5.99E-07
  GOTERM_BP_FAT              GO: 0048858\~cell projection morphogenesis                           34      3.81E-10   6.71E-07
  GOTERM_BP_FAT              GO: 0032989\~cellular component morphogenesis                        44      9.76E-10   1.72E-06
  **Cellular components**                                                                                            
  GOTERM_CC_FAT              GO: 0044459\~plasma membrane part                                    143     3.59E-12   4.94E-09
  GOTERM_CC_FAT              GO: 0005886\~plasma membrane                                         209     1.82E-11   2.50E-08
  GOTERM_CC_FAT              GO: 0031012\~extracellular matrix                                    38      6.62E-09   9.12E-06
  GOTERM_CC_FAT              GO: 0031226\~intrinsic to plasma membrane                            81      2.56E-07   3.52E-04
  GOTERM_CC_FAT              GO: 0005578\~proteinaceous extracellular matrix                      33      3.60E-07   4.95E-04
  GOTERM_CC_FAT              GO: 0005887\~integral to plasma membrane                             77      1.66E-06   0.002279
  GOTERM_CC_FAT              GO: 0030054\~cell junction                                           41      9.84E-06   0.013541
  GOTERM_CC_FAT              GO: 0044421\~extracellular region part                               63      1.28E-05   0.017682
  GOTERM_CC_FAT              GO: 0031224\~intrinsic to membrane                                   250     1.64E-05   0.022599
  GOTERM_CC_FAT              GO: 0045202\~synapse                                                 31      2.48E-05   0.034146
  **Molecular function**                                                                                             
  GOTERM_MF_FAT              GO: 0043565\~sequence-specific DNA binding                           55      3.39E-09   5.13E-06
  GOTERM_MF_FAT              GO: 0015267\~channel activity                                        36      6.24E-06   0.00943
  GOTERM_MF_FAT              GO: 0022836\~gated channel activity                                  30      6.40E-06   0.009679
  GOTERM_MF_FAT              GO: 0022803\~passive transmembrane transporter activity              36      6.57E-06   0.009928
  GOTERM_MF_FAT              GO: 0022838\~substrate specific channel activity                     35      7.55E-06   0.011411
  GOTERM_MF_FAT              GO: 0003700\~transcription factor activity                           65      8.48E-06   0.012823
  GOTERM_MF_FAT              GO: 0005216\~ion channel activity                                    33      2.54E-05   0.038459
  GOTERM_MF_FAT              GO: 0008066\~glutamate receptor activity                             8       1.25E-04   0.188624
  GOTERM_MF_FAT              GO: 0030528\~transcription regulator activity                        84      2.57E-04   0.387228
  GOTERM_MF_FAT              GO: 0005230\~extracellular ligand-gated ion channel activity         11      3.51E-04   0.528754

###### 

Ten KEGG pathways most strongly enriched by target genes.

  Term                                       Input number   Background number   P-value    Corrected P-value
  ------------------------------------------ -------------- ------------------- ---------- -------------------
  Pentose and glucuronate interconversions   11             36                  1.99E-06   0.000464663
  Ascorbate and aldarate metabolism          9              27                  9.55E-06   0.001117413
  Starch and sucrose metabolism              12             56                  1.56E-05   0.001218749
  Porphyrin and chlorophyll metabolism       10             42                  3.67E-05   0.00214613
  Drug metabolism -- other enzymes           10             46                  7.14E-05   0.002817806
  Axon guidance                              17             127                 7.23E-05   0.002817806
  Steroid hormone biosynthesis               11             58                  9.26E-05   0.003093956
  Retinol metabolism                         11             65                  0.000225   0.006578928
  Protein digestion and absorption           12             90                  0.000829   0.021546285
  Drug metabolism -- cytochrome P450         10             68                  0.001135   0.0265701

###### 

Top ten co-expression relationships by STRING.

  Node 1   Node 2   Node 1 string internal id   Homology   Coexpression   Experimentally determined interaction   Database annotated   Automated textmining   Combined score
  -------- -------- --------------------------- ---------- -------------- --------------------------------------- -------------------- ---------------------- ----------------
  TGFBR2   SMAD7    1853779                     0          0.072          0.807                                   0.9                  0.712                  0.994
  PRKG1    PDE5A    1856026                     0          0.207          0.833                                   0                    0.961                  0.994
  ACVRL1   TGFBR2   1857773                     0.77       0.077          0.857                                   0.9                  0.809                  0.988
  LDB3     ACTN2    1860278                     0          0.215          0.933                                   0                    0.789                  0.988
  BMPR2    SMAD7    1856145                     0          0.072          0.573                                   0.9                  0.728                  0.987
  CENPL    CENPM    1853309                     0          0              0.33                                    0.9                  0.753                  0.982
  JDP2     JUND     1845956                     0          0              0.874                                   0                    0.853                  0.98
  WDHD1    GINS4    1854036                     0          0.131          0.95                                    0                    0.584                  0.98
  TCF4     TAL1     1853052                     0          0              0.96                                    0                    0.484                  0.978
  FZD4     WNT3     1861957                     0          0              0.274                                   0.9                  0.714                  0.977
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